Home

Personnel

Publications

Newsletters

Glossary

Bibliography

Calendar

Services

Products

Instructions,
Descriptions,
Manuals

Links

 

 

 

08/12/2002  8:59 am

Inhalation Toxicology Newsletter

jaegerr-2@idt.net

Inhalation Toxicology and Respiratory Biology Newsletter, August, 2002

Greetings,

This is the Summer, 2002, issue of the Inhalation Toxicology newsletter.  Sue Shami (mailto:sshami@mindspring.com) will be Science Editor.

Arlene Weiss will be responsible for Environmental Medicine.   Rudy Jaeger will remain the Publisher.

Address all complaints to him and compliments to Susan.


INFECTIOUS AEROSOL GENERATION DEVICES COMPARED

The BioAerosol Nebulizing Generator (BANG), one and three jet models developed by Bob Gussman, have begun to see a significant increase in the number of users. A number of generators have been deployed to SUNY-Buffalo, USAMRIID, the Harvard School of Public Health (Dr. Melvin First), among other research and testing locations. A six jet version is being developed by Bob Gussman and Kevin DeVoe. The finished unit will be available through CH Technologies (USA) Inc. It will serve a variety of inhalation systems and have utility in environmental assessment.

A technical presentation by B. Goodenow and C. Roy, researchers in the Division of Toxinology and Aerobiology at USAMRIID, Fort Dietrich, MD compares the 3 jet BANG with the BGI 3 jet Collison nebulizer. A copy of the presentation in Powerpoint formats can be found at http://www.inhalation.net.

Note that, after drying, the BANG produces an infectious aerosol in the 0.5 micron range whereas the Collison produced aerosol is around 1 micron. Unlike the Collison nebulizer, the BANG uses a pumped liquid feed system that allows for control of generation rate.

For more information about the poster and the methods used, you may wish to contact Dr. Chad Roy at mailto:chad.roy@amedd.army.mil.

CIGARETTE SMOKE EXPOSURE METHODS

There is a recent interest in the development of aggressive (and non-traditional) protocols for exposure of animals to cigarette smoke. Mice are the favored species. The particular need is for the development of an acute inflammatory response model and the study of COPD (see AIT meeting notice at the end of this newsletter). A number of investigators have reported work in this area using mice, rats and guinea pigs. To be best of our knowledge, rabbits have not yet been used in such work but we could be corrected by our readers.

In chronic exposure studies, mice are reported to be more sensitive to some effects while rats are reported to be resistant (See March et al., "Cigarette Smoke Exposure Produces more Evidence of of Emphysema in B6C3F1 Mice than in F344 Rats", Tox. Sci. 51, 289-299 1999).

The literature reports that there appear to be differences between mouse strain responsiveness in long term tobacco smoke exposure studies where emphysema is the endpoint of concern. We note these are non-standard exposures and are difficult to quantify dosimetrically.

The UC Davis Toxicology group (Witschi, Pinkerton and others) have reported that mice are refractory to an acute inflammatory response after smoke exposure but they do respond when aged diluted cigarette smoke is followed with ozone exposure (Yu et al., "Short-Term Exposure to Aged and Diluted Sidestream Cigarette Smoke Enhances Ozone-Induced Lung Injury in B6C3F1 Mice." Tox. Sci. 65, 99-106, 2002)..  See Dr. Shami's summary at http://www.inhalation.net/yuetal.html.

Other work by Dr. Kent Pinkerton at UC Davis suggests that hypertensive rats show a prompt and substantial inflammatory response whereas normal rats do not.  Readers are invited to comment.

Association of Inhalation Toxicologists (AIT) to meet in Germany on September 18 - 20, 2002

In case you were wondering where to find an Inhalation Toxicologist when you need one, AIT, in addition to the Society of Toxicology Speciality Section on Inhalation Toxicology, is another organization (founded in 1980 or so) that is active in this area. See http://www.inhalation.net for their announcement or send email to: mailto:ait@inveresk.com. The meeting subjects will include Chronic Obstructive Pulmonary Disease (COPD) produced by cigarette smoke among other factors and the use of Juvenile Models in Inhalation Toxicology.

To be automatically added to the mailing list,

send email to the following address:

mailto:jaegerr-2@idt.net?subject=add

Similarly, to be removed from the list,

send e-mail to this address:

mailto:jaegerr-2@idt.net?subject=remove

Responsible Person: Rudy Jaeger - mailto:jaegerr@bellatlantic.net  Send complaints& suggestions for change to the address above.